Are Testosterone Pellets Safe to Use in Perimenopause?

What Are Testosterone Pellets and How Do They Work?

Testosterone pellets are small, cylindrical implants, roughly the size of a grain of rice, inserted subcutaneously into the upper outer buttock or hip under local anesthesia during a brief in-office procedure. They release testosterone continuously over 3 to 5 months, avoiding the daily variation seen with creams or injections. For perimenopausal women, this steady-state delivery is considered one of the format's main practical advantages.

Composition and Delivery Mechanism

Most pellets dispensed to women in the United States are compounded by 503A or 503B pharmacies using crystalline testosterone fused into a cylindrical pellet, typically without binders. Because no finished drug product has received FDA approval for this route in women, every pellet insertion for a female patient constitutes off-label use of a compounded preparation. The FDA regulates compounding pharmacies under different standards than commercially manufactured drugs, which means batch-to-batch potency can vary by as much as 10 to 15 percent in non-503B facilities [1].

Why Perimenopause Affects Testosterone Levels

Testosterone in women is produced primarily by the ovaries and adrenal glands. During perimenopause, which can begin 4 to 10 years before the final menstrual period, ovarian output of both estradiol and testosterone becomes erratic. Total testosterone in women peaks in the mid-twenties and declines roughly 50 percent by the time of natural menopause [2]. That gradual decline, layered on top of the hormonal volatility of perimenopause, can contribute to symptoms including reduced libido, fatigue, difficulty concentrating, and mood instability.

The Pellet vs. Other Testosterone Delivery Routes

Compounded testosterone is also available as topical cream, transdermal gel, injectable cypionate, and sublingual troches. Pellets are unique in that serum levels peak at 4 to 6 weeks post-insertion, then decline slowly. They do not allow rapid dose adjustment. That characteristic matters clinically: if a woman develops androgenic side effects after insertion, no intervention will lower her testosterone until the pellet is substantially absorbed, a process that may take 3 months or longer.

What Does the Evidence Say About Efficacy in Perimenopause?

The strongest evidence for testosterone therapy in women focuses on hypoactive sexual desire disorder (HSDD). Evidence for broader perimenopausal symptom relief, including mood, cognition, and energy, is suggestive but not yet definitive for pellets specifically.

HSDD and Sexual Function

A 2019 position statement from the International Society for the Study of Women's Sexual Health (ISSWSH) and the International Menopause Society concluded that testosterone therapy produces "a statistically and clinically meaningful improvement in sexual function" in postmenopausal women [3]. The data in perimenopausal women are thinner, but the biological rationale is the same. The APHRODITE trial (N=814) tested a 300 mcg/day testosterone patch in surgically menopausal women not receiving estrogen and found a statistically significant increase in satisfying sexual events versus placebo at 24 weeks [4]. Pellet-specific trials are fewer. A 2012 study by Glaser et al. (N=311) using subcutaneous testosterone pellets in women with low testosterone found improvements in sexual desire, depression scores, and joint pain at 6 months compared to pre-treatment baselines, though it lacked a placebo arm [5].

Mood, Cognition, and Energy

Observational data suggest women receiving testosterone pellets report improvements in fatigue and mood within 6 to 8 weeks of insertion. A prospective cohort by Glaser and Dimitrakakis (N=528) followed women receiving pellet therapy over 2 years and found sustained patient-reported improvements in energy and anxiety without significant adverse events at their monitored dose range [6]. These are not randomized controlled trials, and confounding by concurrent estrogen use and the placebo effect of any active intervention cannot be excluded.

Bone Density

Testosterone is aromatized to estradiol in peripheral tissues. Some evidence suggests testosterone supplementation may support bone mineral density in women, separate from its androgenic effects. A 24-month open-label study in hysterectomized women found that subcutaneous testosterone implants maintained lumbar spine bone density at levels comparable to estrogen-only therapy [7]. Perimenopause is when bone loss accelerates, so this potential benefit is clinically relevant, though it should not be the sole reason to choose pellets over other hormone preparations.

What Are the Safety Concerns and Risks?

Testosterone pellets carry real risks in women, and the primary safety issue is supraphysiologic dosing. Virilization can be permanent. That point deserves emphasis before any other discussion of risk.

Virilization and Androgenic Side Effects

Androgenic side effects in women receiving testosterone therapy include acne, oily skin, increased facial and body hair (hirsutism), clitoral enlargement, and voice deepening. Voice changes and clitoral enlargement may not fully reverse after pellet absorption ends. The Endocrine Society's 2014 Clinical Practice Guideline states: "We recommend against the generalized use of testosterone by women because the indications are inadequate, and we are concerned about long-term safety" [8]. That conservative position reflects the fact that high-quality long-term data specific to women, and specific to pellets, are limited.

Cardiovascular Risk

In men, supraphysiologic testosterone raises hematocrit and may adversely affect lipid profiles. In women, data are less developed. A 2021 systematic review in the Journal of Clinical Endocrinology and Metabolism examined cardiovascular outcomes in women receiving testosterone therapy and found no significant increase in adverse cardiovascular events at physiologic doses over 2-year follow-up periods, but acknowledged that studies were underpowered to detect rare events [9]. Women with pre-existing dyslipidemia or cardiovascular risk factors need individualized risk-benefit analysis before pellet insertion.

Breast Cancer Uncertainty

Whether testosterone therapy increases or decreases breast cancer risk in women is not settled. Testosterone can aromatize to estradiol in breast tissue, potentially stimulating estrogen-receptor-positive tumors. Conversely, some preclinical evidence suggests testosterone may have anti-proliferative effects on breast tissue via androgen receptors [10]. The Glaser cohort reported a lower-than-expected incidence of breast cancer in their pellet-treated population, but that observation came from a non-randomized, non-blinded dataset and cannot be used to draw causal conclusions. Women with BRCA mutations or a personal history of hormone-receptor-positive breast cancer should not receive testosterone pellets outside of an oncology-supervised research setting.

Pellet Cannot Be Removed

This point is the most practically significant safety concern unique to the pellet delivery route. Once inserted, the pellet cannot be extracted without a surgical excavation that is rarely performed and often incomplete. A woman who develops unacceptable side effects at week 2 after insertion must simply wait. Clinicians using pellets should start at the lower end of the dose range (50 mg for most women) and increase on the second or third insertion cycle if response was inadequate and levels remained subtherapeutic.

How Are Testosterone Pellets Dosed and Monitored in Women?

Dosing in women is dramatically lower than in men. Male pellet protocols typically use 900 to 1,800 mg per insertion. Women receive 50 to 100 mg, occasionally 150 mg if prior cycles showed subtherapeutic response. These are not interchangeable protocols.

Pre-Insertion Lab Work

Before the first pellet insertion, the following labs should be drawn in the morning, ideally on cycle days 2 to 5 if the patient still has menstrual cycles:

• Total testosterone (LC-MS/MS preferred over immunoassay for accuracy at low female ranges)
• Free testosterone
• Sex hormone-binding globulin (SHBG)
• Estradiol
• FSH and LH
• Complete blood count (CBC)
• Comprehensive metabolic panel
• Fasting lipid panel

Women with SHBG above 80 nmol/L may have biologically low free testosterone despite normal total levels. SHBG elevation is common in women taking oral estrogen or oral contraceptives, because oral estrogen dramatically increases hepatic SHBG production [11]. Switching from oral to transdermal estrogen before reassessing testosterone levels is often the appropriate first step.

Post-Insertion Monitoring Schedule

The following monitoring framework reflects current best practices synthesized from the Endocrine Society guideline [8], the ISSWSH position statement [3], and the clinical protocols described in published pellet cohort studies [5, 6]:

• Week 4 to 6 post-insertion: Total and free testosterone, SHBG, estradiol, and CBC. This is when serum levels peak and the risk of supraphysiologic values is highest.
• Month 3: Repeat testosterone and CBC if week 4 to 6 levels were high-normal or elevated.
• Before each re-insertion: Full hormone panel. Do not re-insert while testosterone remains above 70 ng/dL total in a woman with dose-related side effects.
• Annual: Fasting lipids, liver enzymes, and DEXA scan in women at elevated fracture risk.

What Serum Levels Are Targets?

The physiologic range for total testosterone in premenopausal women is approximately 15 to 70 ng/dL by LC-MS/MS. Pellet therapy in women should aim to keep total testosterone at the mid-to-upper end of that range, not above it. Levels consistently above 100 ng/dL in women are associated with androgenic side effects and should prompt dose reduction on the next cycle.

Who Is a Candidate for Testosterone Pellets During Perimenopause?

Not every perimenopausal woman with fatigue or reduced libido is a candidate for pellet therapy. The clearest indication remains documented low testosterone with confirmed HSDD that has not responded to non-hormonal interventions.

Appropriate Candidates

A perimenopausal woman may be a reasonable candidate for testosterone pellets if she meets all of the following criteria:

1. Documented low or low-normal total testosterone on LC-MS/MS (below 25 ng/dL on two morning draws).
2. Clinically significant symptoms attributable to androgen deficiency, specifically reduced sexual desire causing personal distress (meeting HSDD criteria).
3. No personal history of hormone-receptor-positive breast cancer, untreated polycythemia, or severe androgenic alopecia.
4. Willingness and ability to return for follow-up labs at 4 to 6 weeks post-insertion.
5. Understanding that the pellet cannot be removed and that side effects, if they occur, must resolve through natural pellet absorption.

Women Who Should Avoid Pellets

Women should not receive testosterone pellets if they have a hematocrit above 48 percent, active or recent hormone-receptor-positive breast cancer, untreated sleep apnea, or a desire for rapid dose titration flexibility. For women in those categories, compounded topical testosterone cream at 0.5 to 2 mg per gram applied daily offers more precise dose adjustment and a shorter half-life.

How Do Testosterone Pellets Compare to FDA-Approved Options?

There is currently no FDA-approved testosterone product for women in the United States. The testosterone patch Intrinsa was approved in Europe but was withdrawn for commercial reasons, not safety. In the U.S., the only FDA-approved treatment for HSDD is flibanserin (Addyi), a non-hormonal oral agent taken daily, and bremelanotide (Vyleesi), a subcutaneous injection taken before anticipated sexual activity.

Why No FDA Approval for Testosterone Pellets?

The FDA approved testosterone products for men after large, multi-site randomized controlled trials. No pellet manufacturer has completed the Phase 3 trial program required for New Drug Application (NDA) approval for a female indication. The cost of such a program, combined with the compounded-pharmacy business model, means this is unlikely to change in the near term. Prescribers and patients should understand this regulatory gap when making decisions.

Compounding Pharmacy Quality Matters

A 503B outsourcing facility registered with the FDA operates under current good manufacturing practice (cGMP) standards, meaning potency and sterility testing requirements approach those of commercial manufacturers. A 503A pharmacy compounds for individual patient prescriptions under less intensive oversight. Women receiving testosterone pellets should ask their prescriber whether the pellets come from a 503B facility. The FDA maintains a public list of registered 503B outsourcing facilities [1].

What Should a Perimenopause Consultation Include Before Pellet Insertion?

A thorough consultation before pellet insertion is not a formality. It is the mechanism by which inappropriate candidates are screened out and appropriate ones are counseled adequately.

History and Physical Components

The consultation should include a detailed menstrual history to stage perimenopause, a personal and family history of breast and ovarian cancer, cardiovascular risk factor assessment including blood pressure and fasting glucose, a review of all current medications (particularly oral estrogen and oral contraceptives, which suppress testosterone), and a validated sexual function questionnaire such as the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS).

Informed Consent Specifics

Informed consent for testosterone pellets in women should specifically address: the off-label and compounded status of the therapy; the inability to remove the pellet if side effects occur; the risk of permanent or prolonged virilization with supraphysiologic dosing; the uncertainty of long-term breast cancer and cardiovascular data; and the need for monitoring labs at the patient's expense if not covered by insurance.

The ISSWSH position statement notes that "testosterone therapy for women should only be prescribed by clinicians knowledgeable about the therapy and potential risks, and women should be fully informed about the off-label nature and current evidence limitations" [3].

Frequently Asked Questions